Rallybio Corp (RLYB) [Rocket]

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19
	10-K	8-K	10-K	8-K	10-K	S-1/A
Revenues	0.0	40.7	0.0	26.9	0.0	11.4
Revenue growth		51.2%			-100.0%
Cost of goods sold	0.0	67.9	0.0	45.6	0.0	17.6
Gross profit	0.0	-27.2	0.0	-18.7	0.0	-6.3
Gross margin		-66.8%		-69.6%		-55.2%
Selling, general and administrative [+]	27.2	27.2	18.7	18.7	7.7	6.3
General and administrative	27.2	27.2	18.7	18.7	7.7	6.3
Research and development	40.7		26.9		17.6
Equity in earnings	1.1		1.5		-1.5
Other operating expenses		13.5		8.2		5.1
EBITDA [+]	-66.6		-44.0		-26.8	-17.6
EBITDA growth	51.3%	48.7%	64.5%		51.9%
EBITDA margin		-166.8%		-169.6%		-155.0%
Depreciation and amortization	0.2		0.1		0.1	0.0
EBIT [+]	-66.8	-67.9	-44.1	-45.6	-26.8	-17.6
EBIT growth	51.3%	48.7%	64.6%		52.1%
EBIT margin		-166.8%		-169.6%		-155.2%
Interest income, net [+]			0.0	0.0	0.0	0.2
Interest expense			0.0	0.0	0.0	0.0
Interest income						0.2
Other income (expense), net	1.2	2.3	-1.4	0.2	1.9	0.0
Pre-tax income	-65.6	-65.6	-45.5	-45.5	-24.9	-17.5
Income taxes	0.0	1.1	0.0	1.5	0.0	0.0
Tax rate	0.0%		0.0%		0.1%	0.0%
Net income	-66.7	-66.7	-47.0	-47.0	-26.4	0.0
Net margin		-163.8%		-174.7%		0.0%

Basic EPS [+]	($2.09)	($2.09)	($1.84)	($1.84)	($1.52)
Growth	13.7%	13.7%	21.1%
Diluted EPS [+]	($2.09)	($2.09)	($1.84)	($1.84)	($1.52)
Growth	13.7%	13.7%	21.1%

Shares outstanding (basic) [+]	31.8	31.8	25.5	25.5	17.4
Growth	24.7%	24.7%	46.8%
Shares outstanding (diluted) [+]	31.8	31.8	25.5	25.5	17.4
Growth	24.7%	24.7%	46.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.